Table 4

Characteristics of patients diagnosed with a haematological malignancy (HM) and systemic lupus erythematosus (SLE) concurrently*

ANA7/7(100%)
dsDNA Ab5/7(71%)
Phospholipid Ab2/7(29%)
Arthritis7/7(100%)
Haematological5/7(71%)
Nephritis0/7(0%)
Plaquenil (SLE)6/7(86%)
Methotrexate (SLE)1/7(14%)
Chemotherapy (HM)5/7(71%)
  • *The two diagnoses were made within 1 year of each other (mean, 4 months).

  • Ab, antibody; ANA, antinuclear antibody; dsDNA, double-stranded DNA.